Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568997 | 0.91 | ALDH1A1 (0.49) | RAB9AALDH1A1NPC1LMNAMEN1 | |
| SCHEMBL5567942 | 0.90 | KDM4E (0.48) | RAB9AALDH1A1NPC1LMNAMEN1 | |
| SCHEMBL5568769 | 0.90 | KAT6A (0.42) | RAB9AALDH1A1LMNA | |
| SCHEMBL5565867 | 0.85 | MAPK13 (0.44) | MEP1BAKR1C3NPC1 | |
| SCHEMBL5569155 | 0.85 | ALDH1A1 (0.47) | RAB9AALDH1A1NPC1LMNAMEN1 | |
| SCHEMBL5568580 | 0.84 | F13A1 (0.50) | RAB9AALDH1A1NPC1 | |
| SCHEMBL5568928 | 0.84 | MAPK13 (0.45) | MEP1BAKR1C3NPC1 | |
| SCHEMBL5564428 | 0.84 | NPY5R (0.56) | — | |
| SCHEMBL5568799 | 0.82 | MEP1B (0.43) | MEP1BALDH1A1AKR1C3 | |
| SCHEMBL5565863 | 0.82 | MAPK13 (0.45) | MEP1BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480976-B1 | THIAZOLE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-6686381-B2 | COMPOUNDS THAT ANTAGONIZE NEUROPEPTIDE Y AT THE Y5 RECEPTOR SUBTYPE REPRESENT AN APPROACH TO THE TREATMENT OF EATING DISORDERS SUCH AS OBESITY AND HYPERPHAGIA | HOFFMANN-LA ROCHE INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030225141-A1 | THIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225141-A1 | THIAZOLE DERIVATIVES | SLC5A1, GPR119, TAS1R1 | MEP1B 3012/4885RAB9A 801/4885ALDH1A1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.